Patients who have had an acute coronary syndrome are at high risk for recurrent ische mic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving highintensity statin therapy.
n engl j med nejm.org D espite the availability of current evidencebased treatments, patients who have had an acute coronary syndrome remain at high risk for recurrent ischemic car diovascular events. 1, 2 This residual risk is attrib utable in part to elevated levels of lowdensity lipoprotein (LDL) cholesterol and other athero genic lipoproteins. Previous clinical trials have shown that the risk is lower among patients who receive statin therapy to lower the LDL choles terol level than among those who receive place bo, 3 among patients who receive highintensity statins than among those who receive moderate intensity statins, 4 and among patients who receive ezetimibe added to statin therapy than among those who receive a statin alone. 5 Proprotein convertase subtilisin-kexin type 9 (PCSK9) promotes degradation of LDL receptors, thereby diminishing the clearance of LDL from the circulation. 6 Studies have shown that muta tions conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL choles terol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease. These findings have led to the development of monoclonal anti bodies to PCSK9 that produce substantial reduc tions in LDL cholesterol when administered alone or with a statin. 812 Two of these agents were reported to reduce the risk of ischemic cardio vascular events in patients who had stable athero sclerotic disease or high cardiovascular risk and an elevated level of atherogenic lipoproteins de spite statin treatment, 11, 13 with one agent show ing benefit only among patients who had a base line LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12 To date, the potential for a PCSK9 antibody to reduce cardiovascular risk after an acute coro nary syndrome remains undetermined. In the ODYSSEY OUTCOMES trial, we tested the hypoth esis that treatment with alirocumab, a fully hu man monoclonal antibody to PCSK9, 1315 would result in a lower risk of recurrent ischemic car diovascular events than placebo among patients who had an acute coronary syndrome within the preceding 1 to 12 months and who have levels of atherogenic lipoproteins that exceed specified thresholds despite statin therapy at a highinten sity dose or at the maximum tolerated dose.
Me thods

Trial Organization and Oversight
Details of the trial design have been reported previously. 14 ODYSSEY OUTCOMES was a multi center, randomized, doubleblind, placebocon trolled trial that was sponsored by Sanofi and Regeneron Pharmaceuticals. The protocol and statistical analysis plan (available with the full text of this article at NEJM.org) were conceived by the first three authors, developed in conjunc tion with the other members of the executive steering committee and sponsors, and approved by the responsible regulatory authorities and eth ics committees. The sponsors participated in the selection of the trial sites, the monitoring of the trial, and the supervision of data collection. Duke Clinical Research Institute led the blinded adju dication of the end points. An independent data and safety monitoring committee monitored the safety and efficacy data. Analyses were performed independently by the academic statistician (the third author) in parallel with the sponsors. The manuscript was prepared by the first author with input from all the authors. The members of the executive steering committee made the decision to submit the manuscript for publica tion and vouch for the completeness and accu racy of the data and for the fidelity of the trial to the protocol.
Trial Population
Patients were eligible for enrollment in the trial if they were 40 years of age or older, had been hospitalized with an acute coronary syndrome (myocardial infarction or unstable angina) 1 to 12 months before randomization, and had an LDL cholesterol level of at least 70 mg per deci liter (1.8 mmol per liter), a non−highdensity lipo protein (HDL) cholesterol level of at least 100 mg per deciliter, or an apolipoprotein B level of at least 80 mg per deciliter. All qualifying lipid levels were measured after a minimum of 2 weeks of stable treatment with atorvastatin at a dose of 40 to 80 mg once daily, rosuvastatin at a dose of 20 to 40 mg once daily, or the maximum toler ated dose of one of these statins (including no statin in the case of documented unacceptable side effects). Full trial enrollment criteria are pro vided in the Supplementary Appendix, available n engl j med nejm.org at NEJM.org. All the patients provided written informed consent.
Trial Procedures
During a prerandomization runin phase (de scribed in the Supplementary Appendix), patients received instruction in injecting themselves (with placebo), and lipid levels were verified for patient eligibility. Patients who met trial entry criteria were randomly assigned, in a 1:1 ratio, to receive alirocumab at a dose of 75 mg or matching pla cebo; randomization was stratified according to country (Table S1 in the Supplementary Ap pendix). All doses of alirocumab or placebo were administered by subcutaneous injection every 2 weeks.
The trialgroup assignments and lipid levels during the trial were concealed from the pa tients and investigators. LDL cholesterol levels were calculated with the use of the Friedewald formula unless the triglyceride level exceeded 400 mg per deciliter (4.52 mmol per liter) or the calculated LDL cholesterol level was found to be less than 15 mg per deciliter (0.39 mmol per liter), in which case values were determined by beta quantification. Among patients assigned to the alirocumab group, protocolspecified doseadjust ment algorithms 14 were used to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter) and to avoid sustained levels below 15 mg per deciliter (details can be found in the Additional Information on the Methods and Results section and in Figs. S1 and S2 in the Supplementary Appendix). Dose adjust ments were performed under blinded conditions, without either the patient or the investigator be ing aware of the adjustment, including substitu tion of placebo for alirocumab in the case of sustained levels of LDL cholesterol below 15 mg per deciliter.
Trial End Points
The primary end point was a composite of death from coronary heart disease, nonfatal myocar dial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Pre specified main secondary end points were any coronary heart disease event (death from coro nary heart disease, nonfatal myocardial infarc tion, unstable angina requiring hospitalization, or an ischemiadriven coronary revascularization procedure); major coronary heart disease event (death from coronary heart disease or nonfatal myocardial infarction); any cardiovascular event (death from cardiovascular causes, nonfatal ische mic stroke, nonfatal myocardial infarction, un stable angina requiring hospitalization, or an ischemiadriven coronary revascularization pro cedure); a composite of death from any cause, nonfatal myocardial infarction, or nonfatal ische mic stroke; death from coronary heart disease; death from cardiovascular causes; and death from any cause. Individual components of the primary end point, an ischemiadriven coronary revascu larization procedure, and hospitalization for con gestive heart failure were additional secondary end points. All primary and secondary end points were adjudicated by physicians who were un aware of the trialgroup assignments.
Statistical Analysis
Efficacy was determined by the time to the first occurrence of any component of the composite primary end point; analyses were performed ac cording to the intentiontotreat principle and included data from all patients and for all events that occurred from the time of randomization to the common trial end date. Design assumptions included an incidence of the composite primary end point of 11.4% at 4 years in the placebo group and a median baseline LDL cholesterol level of 90 mg per deciliter (2.3 mmol per liter), with an anticipated 50% lower LDL cholesterol level in the alirocumab group than in the pla cebo group, which would result in an expected 15% lower risk of the primary end point with alirocumab than with placebo. It was estimated that 1613 composite primary endpoint events occurring in 18,000 patients over a median fol lowup of approximately 3 years would provide the trial with 90% power to detect the expected difference in risk at a significance level of 0.05. In China, 614 patients underwent randomization after random assignment of the main trial co hort had been completed (as described in the Supplementary Appendix). The protocol specified that the trial was to continue until at least 1613 primary endpoint events had occurred and all patients who could be evaluated were followed for at least 2 years (except the patients from n engl j med nejm.org China), which would ensure a sufficient obser vation time in which to assess safety and ef ficacy. Patients from China were not followed for 2 years because a lengthy regulatory ap proval process delayed their random assignment to a trial group until after completion of the randomization process for the rest of the trial cohort.
LDL cholesterol was evaluated in an inten tiontotreat analysis that included levels mea sured after premature discontinuation of the trial regimen, levels measured after dose ad justments were made under blinded conditions, and levels measured after blinded substitution of placebo for alirocumab. LDL cholesterol was also evaluated in the alirocumab group in an ontreatment analysis that excluded levels mea sured after premature discontinuation of ali rocumab and levels measured after blinded substitution of placebo for alirocumab but in cluded levels measured after dose adjustments of alirocumab between the 75mg dose and the 150mg dose were made under blinded condi tions.
Hazard ratios and 95% confidence intervals were estimated with the use of a Cox propor tionalhazards model, stratified according to geographic region; P values were determined with the use of stratified logrank tests. To ad just for multiplicity, the results of the main sec ondary end points were to be tested in hierar chical fashion in the sequence listed above if the risk of the composite primary end point was found to be significantly lower in the alirocumab group than in the placebo group. Two prespeci fied interim analyses were performed when approximately 50% and 75% of the planned primary endpoint events for the final analysis had occurred; neither led to early termination of the trial. To account for the two interim analyses, a twosided P value of less than 0.0498 was required to declare statistical sig nificance for the primary end point at the final analysis. Absolute treatment effects in prespeci fied subgroups were compared with the use of the Gail−Simon test. 15 The statistical analysis plan and the Supplementary Appendix provide details of the descriptive safety analyses and analytical methods.
R esult s
Patients, Trial Regimen, and Follow-up
A total of 18,924 patients underwent randomiza tion at 1315 sites in 57 countries; 9462 were assigned to the alirocumab group and 9462 to the placebo group ( Fig. S3 Most of the patients received guidelinerecom mended medications and had undergone coro nary revascularization for the index event. At the time of randomization, 88.8% of the patients were receiving atorvastatin at a dose of 40 mg to 80 mg daily or were receiving rosuvastatin at a dose of 20 mg to 40 mg daily. After 1 year of followup, 84.7% of the patients in the alirocumab group and 86.2% in the placebo group were re ceiving such treatment; after 3 years of follow up, the percentages were 82.8% in the alirocumab group and 86.6% in the placebo group. Infor mation on the adjustment of alirocumab doses under blinded conditions can be found in the Supplementary Appendix.
Patients were followed for a median of 2.8 years (interquartile range, 2.3 to 3.4); the com mon trial end date was November 11, 2017. Pre mature discontinuation of the assigned alirocu mab or placebo for reasons other than death occurred in 1343 patients (14 Body-mass index ‡ 28.5±4.9
28.5±4.8 * Plus-minus values are means ±SD. There were no significant differences between the two groups in demographic or baseline characteristics. Additional baseline characteristics are listed in Table S2 in the Supplementary Appendix. Percentages may not sum to 100 because of rounding. IQR denotes interquartile range. † Race was reported by the patient. ‡ The body-mass index is the weight in kilograms divided by the square of the height in meters. 
Effect of Trial Regimen on Lipid Levels
At baseline, the mean (±SD) LDL cholesterol level was 92±31 mg per deciliter (2.38±0.80 mmol per liter). In the alirocumab group, the mean LDL cholesterol level (intentiontotreat analysis) at 4 months, 12 months, and 48 months after ran domization was 40 mg per deciliter (1.0 mmol per liter), 48 mg per deciliter (1.2 mmol per liter), and 66 mg per deciliter (1.7 mmol per liter), re spectively; in the placebo group, the mean LDL cholesterol level at 4 months, 12 months, and 48 months after randomization was 93 mg per deciliter (2.4 mmol per liter), 96 mg per deciliter (2.5 mmol per liter), and 103 mg per deciliter (2.7 mmol per liter), respectively (Fig. 1 ). In the ontreatment analysis in the alirocumab group (which excluded values measured after discon tinuation of alirocumab and after blinded sub stitution of placebo for alirocumab), the mean LDL cholesterol level at 4 months, 12 months, and 48 months was 38 mg per deciliter (0.98 mmol per liter), 42 mg per deciliter (1.1 mmol per liter), and 53 mg per deciliter (1.4 mmol per liter), re spectively; these levels were an average of 62.7%, 61.0%, and 54.7% lower than the respective levels in the placebo group. Other lipid measure ments are provided in Figure S4 in the Supple mentary Appendix.
End Points
A composite primary endpoint event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group ( Table 2) ; The Kaplan-Meier probability estimate at 4 years was 12.5% in the alirocumab group and 14.5% in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001) (Fig. 2) . To prevent the occurrence of one primary endpoint event, 49 patients (95% CI, 28 to 164) would need to be treated for 4 years. The effect of alirocumab on the relative risk of the composite primary end point did not differ significantly according to any of the prespecified subgroup variables (Fig. S5 in the Supplementary Appendix).
As would be expected, the incidence of the composite primary end point in the placebo group differed across three categories of baseline LDL cholesterol levels (<80, 80 to <100, and ≥100 mg per deciliter), with the greatest incidence among patients in the highest category. Correspond ingly, in a nonprespecified analysis, the greatest absolute reduction in risk of the composite pri mary end point with alirocumab was also shown among the patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter (P<0.001 for the interaction between treatment and baseline LDL cholesterol level) (Table S3 and Fig. S6 in the Supplementary Appendix). To pre vent the occurrence of one primary endpoint event among patients with a baseline LDL cho lesterol level of 100 mg or more per deciliter, 16 patients (95% CI, 11 to 34) would need to be treated for 4 years. Additional analyses related to categories of baseline LDL cholesterol are provided in Table S3 in the Supplementary Ap pendix.
Among the main secondary end points, the risks of any coronary heart disease event, major coronary heart disease events, any cardiovascu The intention-to-treat analysis (results shown with solid lines) included all low-density lipoprotein (LDL) cholesterol values, including levels measured after premature discontinuation of the trial regimen, levels measured after dose adjustments were made under blinded conditions, and levels measured after blinded substitution of placebo for alirocumab. The on-treatment analysis (results shown with dashed lines) excluded LDL cholesterol levels measured after premature discontinuation of the trial regimen and levels measured after blinded substitution of placebo for alirocumab (but included LDL cholesterol levels measured after dose adjustments of alirocumab were made under blinded conditions between the 75-mg dose and the 150-mg dose). To convert the values for LDL cholesterol to millimoles per liter, multiply by 0.02586. 
Months since Randomization
Safety
The incidence of adverse events and of labora tory abnormalities was similar in the alirocumab group and the placebo group (Table 3) , with the exception of local injectionsite reaction (3.8% in the alirocumab group vs. 2.1% in the placebo group, P<0.001). Injectionsite reactions (itching, redness, or swelling) were usually mild and self limited and led to discontinuation of the trial regimen in 26 patients in the alirocumab group, at a median of 8.3 months after randomization, and in 3 patients in the placebo group. Neuro cognitive events were reported in 1.5% of the patients in the alirocumab group and in 1.8% of the patients in the placebo group, newonset diabetes (as defined in the Supplementary Appendix) in 9.6% and 10.1%, respectively, and hemorrhagic stroke (confirmed by adjudication) in less than 0.1% and 0.2%. Neutralizing anti drug antibodies were detected in 0.5% of the patients in the alirocumab group and in less than 0.1% in the placebo group. 
Discussion
Among patients who had a previous acute coro nary syndrome and in whom lipid levels exceeded specified thresholds despite atorvastatin or rosu vastatin therapy at a highintensity dose or at the maximum tolerated dose, the risk of a compos ite of death from coronary heart disease, non fatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization was lower among those who were treated with alirocumab than among those who received placebo. These benefits were ob served in the context of background care that included extensive use of evidencebased treat ments 1619 as well as the use of a doseadjustment strategy for alirocumab that targeted an LDL cholesterol level of 25 to 50 mg per deciliter and allowed a level of 15 to 25 mg per deciliter, but that avoided sustained levels below 15 mg per deciliter.
The absolute benefit of alirocumab with re spect to the composite primary end point was more pronounced among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients with a lower baseline LDL cholesterol level. Similarly, a recent metaanalysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL choles terol level of 100 mg or more per deciliter. 20 Over a median followup period of 2.8 years, with more than 8000 patients who were eligible to be followed for 3 to 5 years and 6444 patients who received the assigned alirocumab or place bo for at least 3 years, the incidence of adverse events did not differ significantly between the two groups, with the exception of local injection site reactions. Whether the safety and efficacy of alirocumab were influenced by the blinded dose adjustment strategy, which was designed to miti gate the occurrence of very low levels of LDL cholesterol, is unknown. Serious safety concerns were also not observed with evolocumab in the FOURIER (Further Cardiovascular Outcomes Re search with PCSK9 Inhibition in Subjects with Elevated Risk) trial, 11 which had no lower limit for allowable LDL cholesterol levels; however, that trial had a shorter median followup, and very few patients were followed for 3 or more years. Neither trial can fully predict longerterm safety of treatment with a PCSK9 monoclonal antibody.
Lowering of LDL cholesterol levels with alirocu mab was sustained but to a lesser extent than that reported in previous trials that had a shorter duration. 9 The increase in LDL cholesterol over time in the intentiontotreat analysis reflects premature discontinuation of treatment, dose reduction or substitution of placebo for alirocu mab under blinded conditions, and attenuation of the intensity of statin treatment. The last fac tor probably also contributed to the rise in LDL cholesterol observed in the placebo group, in the ontreatment analysis in the alirocumab group, and in previous trials involving patients who had an acute coronary syndrome. 5, 21 Antidrug anti bodies were detected in few patients and have been shown not to influence the lipidlowering efficacy of alirocumab. 22 There are noteworthy similarities and dif ferences between our trial and the previous FOURIER and SPIRE (Studies of PCSK9 Inhibi tion and the Reduction of Vascular Events) trials, which evaluated the PCSK9 antibodies evolocu mab and bococizumab, respectively. 11, 13 The cur rent trial and the FOURIER trial showed similar improvements in composite cardiovascular out Shown is the cumulative incidence of the primary efficacy end point (a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization). The Kaplan-Meier rates for the primary end point at 4 years were 12.5% (95% CI, 11.5 to 13.5) in the alirocumab group and 14.5% (95% CI, 13.5 to 15.6) in the placebo group. The inset shows the same data on an enlarged y axis. The P value was calculated with the use of log-rank tests, stratified according to geographic region. n engl j med nejm.org comes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10 Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deci liter. 12 The current trial showed the efficacy of PCSK9 inhibition in highrisk patients who had a previous acute coronary syndrome, 89% of whom received highintensity statin therapy, and used a blinded doseadjustment strategy to achieve a target range of LDL cholesterol with PCSK9 in hibition. The longer duration of followup in the current trial than in previous trials, owing to the mandatory minimum 2year followup, facilitated the assessment of efficacy and safety. A limitation of all three trials is the infrequent use of ezeti mibe, for which cardiovascular efficacy was estab lished 5 after most of the patients had already been enrolled and the trials were well under way.
In conclusion, among patients who had a pre vious acute coronary syndrome and whose levels of atherogenic lipoproteins remained elevated despite statin therapy at a highintensity dose or at the maximum tolerated dose, the risk of major adverse cardiovascular events was lower among those who were treated with alirocumab than among those who received placebo.
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We thank the patients, trial coordinators, and investigators who participated in this trial. * New-onset diabetes was defined according to the presence of one or more of the following, with confirmation of the diagnosis by blinded external review by experts in the field of diabetes: an adverse-event report, a new prescription for diabetes medication, a glycated hemoglobin level of at least 6.5% on two occasions (and a baseline level of <6.5%), or a fasting serum glucose level of at least 126 mg per deciliter (7.0 mmol per liter) on two occasions (and a baseline level of <126 mg per deciliter). † Antidrug antibodies were defined by the presence of positive responses detected after the start of administration of the trial regimen in at least two consecutive postbaseline serum samples, separated by at least a 16-week period. 
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